A Piroxicam Derivative Partly Effective in Chronic Paroxysmal Hemicrania and Hemicrania Continua
Article first published online: 18 MAY 2005
Headache: The Journal of Head and Face Pain
Volume 35, Issue 9, pages 549–550, October 1995
How to Cite
Sjaastad, O. and Antonaci, F. (1995), A Piroxicam Derivative Partly Effective in Chronic Paroxysmal Hemicrania and Hemicrania Continua. Headache: The Journal of Head and Face Pain, 35: 549–550. doi: 10.1111/j.1526-4610.1995.hed3509549.x
- Issue published online: 18 MAY 2005
- Article first published online: 18 MAY 2005
- Accepted for publication April 12, 1995.
- chronic paroxysmal hemicrania;
- hemicrania continua
Piroxicam beta-cyclodextrin has recently been observed to be equal to, or even possibly to be superior to, indomethacin (mainly with regard to side effects) in a single case of hemicrania continua. Piroxicam beta-cyclodextrin, 20 to 40 mg per day, was, accordingly, tried in six patients with chronic paroxysmal hemicrania and six patients with hemicrania continua with a previously proven response to indomethacin. The study was conducted over a period of 3 weeks and in an open fashion. A placebo effect is considered to be negligible in these disorders. In such a comparison, piroxicam beta-cyclodextrin seemed inferior to indomethacin, in particular in chronic paroxysmal hemicrania.